SEC For	m 4																		
FORM 4 UNI				ED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549															
Section 16. Form 4 or Form 5 obligations may continue. See					NT OF CHANGES IN BENEFICIAL OWNE d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									HIP	Estim	OMB Number:     3235-0287       Estimated average burden        hours per response:     0.5			
1. Name and Address of Reporting Person* <u>TRABER PETER G</u>					2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>SELECTA BIOSCIENCES INC</u> [ SELB ]								(Che	ck all applica Director Officer (	able)	10% O ve title Other (		ner	
	(Last) (First) (Middle) C/O SELECTA BIOSCIENCES, INC. 65 GROVE STREET				3. Date of Earliest Transaction (Month/Day/Year)										below) Chief Medical Officer				
(Street) WATERTOWN MA 02472				4	Line)									oint/Group Filing (Check Applicable led by One Reporting Person led by More than One Reporting					
(City)	(5																		
Table I - Non-Deriv   1. Title of Security (Instr. 3)   2. Trans   Date (Month/I)					1			e, 3. 4 Transaction D Code (Instr. 5		4. Secur Dispose	. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		A) or	5. Amoun Securities Beneficia Owned Fe Reported	s For Ily (D) bllowing (I) (		Direct I Indirect I str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount	ount (A) or (D) Pi		Price	Transacti (Instr. 3 a	on(s)			(1150.4)	
Common Stock 01/03					3/2022		A <sup>(1)</sup>		90,20	00	A	\$ <mark>0</mark>			81 D				
			Table II - D (e					juired, Di s, option						Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Ye	Code	action (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exe Expiration (Month/Day	Date	of Securitie		rities ing ve Sec	urity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	or Nu	iount mber Shares		(Instr. 4)	011(3)			
Employee Stock Option (right to buy)	\$3.31	01/03/2022		A		415,900		(2)	01	1/02/2032	Common Stock	<sup>n</sup> 41	5,900	\$0	415,9	00	D		

## Explanation of Responses:

1. Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 3, 2023. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 3, 2026.

2. This option vests as to 25% on January 3, 2023. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter.

## **Remarks:**

<u>/s/ Matthew Bartholomae</u>,

<u>Attorney-in-Fact for Peter G.</u> <u>Traber</u>

\*\* Signature of Reporting Person Date

01/05/2022

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $\ast$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.